Prevalence and Resistance Profiles of Acinetobacter baumannii in ICU Patients in Saudi Arabia: A Systematic Review and Meta-Analysis
Prävalenz und Resistenzprofile von Acinetobacter baumannii bei ICU-Patient:innen in Saudi-Arabien: systematische Übersichtsarbeit und Metaanalyse
Antibiotics · 07.11.2025 · 14 (11) · 1131
DOI: 10.3390/antibiotics14111131 ↗Auf einen Blick
Die Übersichtsarbeit zeigt eine hohe und zwischen Studien stark schwankende Prävalenz von MDR-A. baumannii auf ICU-Patient:innen in Saudi-Arabien. Colistin blieb in einigen Studien wirksam; häufig war Resistenz gegen Carbapeneme hoch.
Fragestellung
Wie hoch sind Prävalenz und Antibiotikaresistenz von MDR-A. baumannii bei ICU-Patient:innen in Saudi-Arabien?
Methode
Systematische Übersichtsarbeit und Metaanalyse; Suche in PubMed, Saudi Digital Library, Scopus und Web of Science von Januar 2014 bis September 2025; Qualitätsbewertung mit Joanna Briggs Institute.
Ergebnisse
Die Prävalenz von MDR-AB variierte: retrospektive Studien 3,37 % bis 69 %, prospektive 3,9 % bis 72,73 %. Colistin zeigte in einigen Studien 100 % Empfindlichkeit; Resistenz gegen Imipenem und Meropenem lag oft über 50 %.
Schlussfolgerung der Autor:innen
MDR-A. baumannii stellt in saudischen ICUs eine erhebliche Herausforderung dar, mit hoher Prävalenz und deutlicher Resistenz gegen häufig verwendete Antibiotika.
Kernaussagen
- MDR-AB-Prävalenz variierte stark zwischen den Studien
- Colistin blieb in einigen Studien wirksam
- Carbapenem-Resistenz lag oft über 50 %
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 07.11.2025. Verfasst von Alaa Alibrahim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, College of Medicine, Jouf University, Sakaka 72388, Saudi Arabia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Graduate Studies and Scientific Research at Jouf University.
Themen: Intensivpflege
Abstract (Originalsprache)
Background
Acinetobacter baumannii (A. baumannii), a critical nosocomial pathogen, poses a significant threat in intensive care units (ICUs) due to its multidrug-resistant (MDR) strains. This study systematically reviews and performs a meta-analysis on the prevalence and antibiotic resistance profiles of MDR A baumannii (MDR-A. baumannii) in ICU patients in Saudi Arabia.
Methods
A comprehensive search in PubMed, Saudi Digital Library, Scopus, and Web of Science, focusing on studies from January 2014 to September 2025, was performed. The present study followed the reporting guidelines of Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA-2020). Data on study characteristics, sample sizes, patient demographics, prevalence of MDR-AB, and antibiotic resistance profiles were extracted and analyzed. Quality assessment was conducted using the Joanna Briggs Institute.
Results
The prevalence of MDR-AB in ICU patients varied significantly across studies, with retrospective studies reporting rates from 3.37% to 69% and prospective studies ranging from 3.9% to 72.73%. Colistin remained highly effective, showing 100% susceptibility in some studies. Meanwhile, resistance to carbapenems like imipenem and meropenem often exceeds 50%. Additional antibiotics with notable resistance included gentamicin, tigecycline, ampicillin/sulbactam, trimethoprim-sulfamethoxazole, ceftazidime, piperacillin/tazobactam, and third-generation cephalosporins. Mechanisms of resistance frequently involved OXA-type carbapenemases, particularly OXA-23. While OXA-23 was the most frequently detected carbapenemase, recent genomic data have also revealed the presence of metallo-β-lactamases, such as IMP-type genes, in ICU isolates.
Conclusions
MDR-A. baumannii poses a substantial challenge in Saudi Arabian ICUs, with high prevalence and significant resistance to commonly used antibiotics. The results highlight the critical need for continuous monitoring, cautious antibiotic stewardship, and strict infection control methods to manage and lessen the effects of MDR-AB in ICUs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, College of Medicine, Jouf University, Sakaka 72388, Saudi Arabia.
- Department of Pathology, College of Medicine, Jouf University, Sakaka 72388, Saudi Arabia.
- Department of Family Medicine, Prince Mohammed Medical City, Aljouf Health Cluster, Sakaka 72346, Saudi Arabia.
- College of Medicine, Jouf University, Sakaka 72388, Saudi Arabia.
- Department of Medicine, Infectious Disease Division, Prince Sultan Military Medical City, Riyadh 11564, Saudi Arabia.
- College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
ORCID-Profile: Alaa Alibrahim, Farooq Ahmed Wani, Mohammed Alsaeed
Förderung
- Deanship of Graduate Studies and Scientific Research at Jouf University
Zitieren
APA
Alibrahim, A., Wani, F. A., Alruwaili, O. S., Altaymani, S., Alharbi, Z. A., Alsubaiei, S., Aldhuwayhi, S., Alsaeed, M., & Alibrahim, M. (2025). Prevalence and Resistance Profiles of Acinetobacter baumannii in ICU Patients in Saudi Arabia: A Systematic Review and Meta-Analysis. Antibiotics, 14(11), 1131. https://doi.org/10.3390/antibiotics14111131
Vancouver
Alibrahim A, Wani FA, Alruwaili OS, Altaymani S, Alharbi ZA, Alsubaiei S, et al. Prevalence and Resistance Profiles of Acinetobacter baumannii in ICU Patients in Saudi Arabia: A Systematic Review and Meta-Analysis. Antibiotics. 2025;14(11):1131. doi:10.3390/antibiotics14111131
BibTeX
@article{Alibrahim2025,
author = {Alibrahim, Alaa and Wani, Farooq Ahmed and Alruwaili, Ohoud Shafi and Altaymani, Sadeem and Alharbi, Zaid Ali and Alsubaiei, Sayyaf and Aldhuwayhi, Saleh and Alsaeed, Mohammed and Alibrahim, Mohammed},
title = {Prevalence and Resistance Profiles of Acinetobacter baumannii in ICU Patients in Saudi Arabia: A Systematic Review and Meta-Analysis},
journal = {Antibiotics},
year = {2025},
volume = {14},
number = {11},
pages = {1131},
doi = {10.3390/antibiotics14111131}
}
EUVIMED